Symbols / RAPP Stock $35.72 +3.93% Rapport Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
RAPP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Abraham N. Ceesay M.B.A.
Exch · Country NGM · United States
Market Cap 1.71B
Enterprise Value 1.18B
Income -107.28M
Sales 20.00M
FCF (ttm) -49.43M
Book/sh 9.86
Cash/sh 9.97
Employees 84
Insider 10d —
IPO Jun 07, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.99
PEG —
P/S 85.42
P/B 3.62
P/C —
EV/EBITDA -9.72
EV/Sales 58.89
Quick Ratio 26.64
Current Ratio 27.08
Debt/Eq 2.29
LT Debt/Eq —
EPS (ttm) -2.60
EPS next Y -4.47
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -19.10%
ROE -28.33%
ROIC —
Gross Margin 34.28%
Oper. Margin -121.08%
Profit Margin 0.00%
Shs Outstand 47.83M
Shs Float 31.34M
Insider Own 4.65%
Instit Own 109.16%
Short Float 10.11%
Short Ratio 8.86
Short Interest 3.05M
52W High 42.27
vs 52W High -15.49%
52W Low 7.73
vs 52W Low 362.10%
Beta —
Impl. Vol. 70.85%
Rel Volume 0.74
Avg Volume 341.38K
Volume 253.08K
Target (mean) $55.90
Tgt Median $54.50
Tgt Low $40.00
Tgt High $80.00
# Analysts 10
Recom Strong_buy
Prev Close $34.37
Price $35.72
Change 3.93%
About

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$55.90
Mean price target
2. Current target
$35.72
Latest analyst target
3. DCF / Fair value
$-18.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$35.72
Low
$40.00
High
$80.00
Mean
$55.90

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 reit BTIG Buy → Buy $53
2026-04-22 reit BTIG Buy → Buy $53
2026-03-11 main BTIG Buy → Buy $53
2026-03-11 main Wells Fargo Overweight → Overweight $46
2026-02-02 init Wells Fargo — → Overweight $43
2025-12-09 main HC Wainwright & Co. Buy → Buy $40
2025-12-08 reit BTIG Buy → Buy $47
2025-11-19 init BTIG — → Buy $47
2025-11-07 main Citizens Market Outperform → Market Outperform $80
2025-09-16 init Truist Securities — → Buy $44
2025-09-08 main HC Wainwright & Co. Buy → Buy $34
2025-08-06 init HC Wainwright & Co. — → Buy $31
2025-07-08 reit JMP Securities Market Outperform → Market Outperform $28
2025-04-08 init JMP Securities — → Market Outperform $28
2024-10-18 init Jones Trading — → Buy $42
2024-07-02 init TD Cowen — → Buy —
2024-07-02 init Jefferies — → Buy $35
2024-07-02 init Stifel — → Buy $35
News
RSS: Latest RAPP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-11 THIRD ROCK VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security — 133,618 $40.24 $5,377,323
2026-05-08 THIRD ROCK VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security — 276,513 $40.12 $11,094,906
2026-04-17 THIRD ROCK VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security — 426,005 $40.32 $17,175,244
2026-04-17 YELESWARAM KRISHNASWAMY Officer — 20,225 $39.99 $808,844
2026-04-14 YELESWARAM KRISHNASWAMY Officer — 19,865 $34.97 $695,823
2026-04-08 YELESWARAM KRISHNASWAMY Officer — 360 $34.90 $12,564
2026-03-30 GAULT CHERYL Chief Operating Officer — 10,000 $28.04 $281,857
2026-03-25 YELESWARAM KRISHNASWAMY Officer — 10,115 $29.99 $303,355
2026-03-05 GAULT CHERYL Chief Operating Officer — 2,014 $28.93 $58,265
2026-02-19 BREDT DAVID Officer — 6,000 $1.80 $10,800
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
125.10
+50.62%
83.06
+129.57%
36.18
Research And Development
94.79
+55.56%
60.94
+117.63%
28.00
Selling General And Administration
30.31
+37.03%
22.12
+170.42%
8.18
General And Administrative Expense
30.31
+37.03%
22.12
+170.42%
8.18
Salaries And Wages
21.52
+53.83%
13.99
+223.52%
4.32
Other Gand A
8.79
+8.12%
8.13
+110.87%
3.86
Total Expenses
125.10
+50.62%
83.06
+129.57%
36.18
Operating Income
-125.10
-50.62%
-83.06
-129.57%
-36.18
Total Operating Income As Reported
-125.10
-50.62%
-83.06
-129.57%
-36.18
EBITDA
-124.08
-50.92%
-82.22
-127.95%
-36.07
Normalized EBITDA
-124.08
-50.92%
-82.22
-127.95%
-36.07
Reconciled Depreciation
1.02
+21.22%
0.84
+649.11%
0.11
EBIT
-125.10
-50.62%
-83.06
-129.57%
-36.18
Total Unusual Items
—
—
-1.12
Total Unusual Items Excluding Goodwill
—
—
-1.12
Net Income
-111.48
-42.37%
-78.31
-125.11%
-34.79
Pretax Income
-111.48
-42.37%
-78.31
-125.18%
-34.78
Net Non Operating Interest Income Expense
13.62
+12.18%
12.14
+380.33%
2.53
Interest Expense Non Operating
—
—
0.00
Net Interest Income
13.62
+12.18%
12.14
+380.33%
2.53
Interest Expense
—
—
0.00
Interest Income Non Operating
13.62
+12.18%
12.14
+380.33%
2.53
Interest Income
13.62
+12.18%
12.14
+380.33%
2.53
Other Income Expense
—
-7.39
-557.47%
-1.12
Other Non Operating Income Expenses
—
-7.39
-557.47%
-1.12
Gain On Sale Of Security
—
—
-1.12
Tax Provision
—
0.00
-100.00%
0.01
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-111.48
-42.37%
-78.31
-125.11%
-34.79
Net Income From Continuing Operation Net Minority Interest
-111.48
-42.37%
-78.31
-125.11%
-34.79
Net Income From Continuing And Discontinued Operation
-111.48
-42.37%
-78.31
-125.11%
-34.79
Net Income Continuous Operations
-111.48
-42.37%
-78.31
-125.11%
-34.79
Normalized Income
-111.48
-42.37%
-78.31
-125.11%
-34.79
Net Income Common Stockholders
-111.48
-42.37%
-78.31
-125.11%
-34.79
Diluted EPS
—
-3.78
+83.64%
-23.10
Basic EPS
—
-3.78
+83.64%
-23.10
Basic Average Shares
—
20.74
+1277.25%
1.51
Diluted Average Shares
—
20.74
+1277.25%
1.51
Diluted NI Availto Com Stockholders
-111.48
-42.37%
-78.31
-125.11%
-34.79
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
512.43
+62.71%
314.93
+102.63%
155.42
+391.80%
31.60
Current Assets
498.56
+60.93%
309.80
+105.34%
150.87
+382.51%
31.27
Cash Cash Equivalents And Short Term Investments
490.54
+60.68%
305.28
+107.00%
147.48
+373.31%
31.16
Cash And Cash Equivalents
52.65
-7.32%
56.80
-19.05%
70.17
+125.20%
31.16
Other Short Term Investments
437.89
+76.23%
248.47
+221.41%
77.31
0.00
Restricted Cash
0.10
+0.00%
0.10
+23.53%
0.09
0.00
Other Current Assets
7.92
+79.24%
4.42
+33.48%
3.31
+2935.78%
0.11
Total Non Current Assets
13.87
+170.32%
5.13
+12.74%
4.55
+1258.51%
0.34
Net PPE
12.88
+159.20%
4.97
+24.28%
4.00
+1094.03%
0.34
Gross PPE
14.87
+150.45%
5.94
+43.83%
4.13
+1079.14%
0.35
Accumulated Depreciation
-1.98
-105.39%
-0.96
-659.84%
-0.13
-746.67%
-0.01
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
1.44
-30.81%
2.08
—
Machinery Furniture Equipment
0.13
+88.06%
0.07
+55.81%
0.04
0.00
Construction In Progress
0.12
-72.56%
0.43
+1553.85%
0.03
-52.73%
0.06
Other Properties
14.33
+177.78%
5.16
+200.06%
1.72
+482.71%
0.29
Leases
0.29
+4.98%
0.28
+10.20%
0.26
0.00
Other Non Current Assets
0.98
+515.63%
0.16
-70.96%
0.55
—
Total Liabilities Net Minority Interest
27.78
+192.22%
9.51
-94.75%
181.06
+334.55%
41.66
Current Liabilities
19.05
+117.28%
8.77
-0.41%
8.80
+429.34%
1.66
Payables And Accrued Expenses
9.17
+112.26%
4.32
-24.44%
5.72
+243.96%
1.66
Payables
4.19
+114.43%
1.95
-21.90%
2.50
+72.55%
1.45
Accounts Payable
4.19
+114.43%
1.95
-21.90%
2.50
+72.55%
1.45
Current Accrued Expenses
4.98
+110.47%
2.37
-26.41%
3.22
+1410.80%
0.21
Pensionand Other Post Retirement Benefit Plans Current
7.12
+92.02%
3.71
+53.67%
2.41
0.00
Current Debt And Capital Lease Obligation
2.75
+273.81%
0.74
+10.00%
0.67
—
Current Capital Lease Obligation
2.75
+273.81%
0.74
+10.00%
0.67
0.00
Total Non Current Liabilities Net Minority Interest
8.73
+1081.19%
0.74
-99.57%
172.25
+330.61%
40.00
Long Term Debt And Capital Lease Obligation
8.73
+1081.19%
0.74
-49.93%
1.48
0.00
Long Term Capital Lease Obligation
8.73
+1081.19%
0.74
-49.93%
1.48
0.00
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
170.78
+326.92%
40.00
Stockholders Equity
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Common Stock Equity
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Capital Stock
0.05
+29.73%
0.04
+825.00%
0.00
+0.00%
0.00
Common Stock
0.05
+29.73%
0.04
+825.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
47.77
+30.60%
36.58
+3.40%
35.38
+0.00%
35.38
Ordinary Shares Number
47.77
+30.60%
36.58
+3.40%
35.38
+0.00%
35.38
Additional Paid In Capital
719.29
+67.41%
429.66
+2070.42%
19.80
+3278.16%
0.59
Retained Earnings
-235.23
-90.09%
-123.75
-172.34%
-45.44
-326.57%
-10.65
Gains Losses Not Affecting Retained Earnings
0.55
+204.60%
-0.52
-13150.00%
0.00
0.00
Other Equity Adjustments
0.55
+204.60%
-0.52
-13150.00%
0.00
—
Total Equity Gross Minority Interest
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Total Capitalization
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Working Capital
479.51
+59.29%
301.04
+111.89%
142.07
+379.88%
29.61
Invested Capital
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Total Debt
11.48
+678.05%
1.48
-31.22%
2.15
0.00
Capital Lease Obligations
11.48
+678.05%
1.48
-31.22%
2.15
0.00
Net Tangible Assets
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Tangible Book Value
484.65
+58.68%
305.43
+1291.49%
-25.63
-154.76%
-10.06
Derivative Product Liabilities
—
—
4.20
-59.75%
10.44
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-87.47
-34.93%
-64.83
-138.50%
-27.18
Cash Flow From Continuing Operating Activities
-87.47
-34.93%
-64.83
-138.50%
-27.18
Net Income From Continuing Operations
-111.48
-42.37%
-78.31
-125.11%
-34.79
Depreciation Amortization Depletion
1.02
+21.22%
0.84
+649.11%
0.11
Depreciation And Amortization
1.02
+21.22%
0.84
+649.11%
0.11
Other Non Cash Items
2.03
-74.70%
8.03
+477.43%
1.39
Stock Based Compensation
18.86
+84.22%
10.23
+190.35%
3.52
Operating Gains Losses
—
7.39
+557.47%
1.12
Gain Loss On Investment Securities
—
7.39
+557.47%
1.12
Change In Working Capital
3.50
+244.95%
-2.42
-191.10%
2.65
Change In Prepaid Assets
-3.60
-94.01%
-1.85
+42.06%
-3.20
Change In Payables And Accrued Expense
8.38
+33424.00%
0.03
-99.60%
6.24
Change In Accrued Expense
6.17
+1561.99%
0.37
-93.10%
5.38
Change In Payable
2.21
+740.17%
-0.35
-140.42%
0.86
Change In Account Payable
2.21
+740.17%
-0.35
-140.42%
0.86
Change In Other Current Assets
-0.79
-1053.01%
0.08
+134.58%
-0.24
Change In Other Current Liabilities
-0.49
+26.72%
-0.67
-365.28%
-0.14
Investing Cash Flow
-187.47
-10.19%
-170.14
-115.75%
-78.86
Cash Flow From Continuing Investing Activities
-187.47
-10.19%
-170.14
-115.75%
-78.86
Net PPE Purchase And Sale
-0.62
+74.39%
-2.40
-47.00%
-1.64
Purchase Of PPE
-0.62
+74.39%
-2.40
-47.00%
-1.64
Capital Expenditure
-0.62
+74.39%
-2.40
-47.00%
-1.64
Net Investment Purchase And Sale
-186.86
-11.40%
-167.74
-117.21%
-77.22
Purchase Of Investment
-354.78
+6.03%
-377.53
-388.88%
-77.22
Sale Of Investment
167.93
-19.96%
209.80
0.00
Financing Cash Flow
270.79
+22.18%
221.62
+52.70%
145.14
Cash Flow From Continuing Financing Activities
270.79
+22.18%
221.62
+52.70%
145.14
Net Issuance Payments Of Debt
—
—
0.00
Issuance Of Debt
—
—
0.00
Repayment Of Debt
—
—
0.00
Long Term Debt Issuance
—
—
0.00
Long Term Debt Payments
—
—
0.00
Net Long Term Debt Issuance
—
—
0.00
Net Common Stock Issuance
269.44
+70.85%
157.71
+315310.00%
0.05
Common Stock Payments
-0.00
0.00
+100.00%
-0.00
Repurchase Of Capital Stock
-0.00
0.00
+100.00%
-0.00
Proceeds From Stock Option Exercised
1.35
+19157.14%
0.01
0.00
Net Other Financing Charges
—
—
-0.13
Changes In Cash
-4.16
+68.82%
-13.34
-134.13%
39.09
Beginning Cash Position
56.91
-18.99%
70.25
+125.47%
31.16
End Cash Position
52.75
-7.31%
56.91
-18.99%
70.25
Free Cash Flow
-88.09
-31.02%
-67.23
-133.31%
-28.82
Amortization Of Securities
-1.40
+56.52%
-3.21
-4181.33%
-0.07
Common Stock Issuance
269.44
+70.85%
157.71
+291946.30%
0.05
Issuance Of Capital Stock
269.44
+21.58%
221.62
+52.55%
145.27
Net Preferred Stock Issuance
0.00
-100.00%
63.91
-55.99%
145.22
Preferred Stock Issuance
0.00
-100.00%
63.91
-55.99%
145.22
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category